Repurposed Drug Shows Promise for Ovarian Cancer Survival

A clinical trial shows that Relacorilant, a drug typically used for Cushing’s syndrome, may extend survival for patients with platinum-resistant ovarian cancer. This aggressive cancer type progresses within six months of platinum-based chemotherapy, highlighting the need for effective treatment options.

Read the full story at The Guardian AU→